The JRKL Knockout NCI-H1975 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal knockout cell population targeting the JRKL gene. This pooled model provides a genetically heterogeneous background for functional studies in a human non-small cell lung cancer (NSCLC) context, avoiding monoclonality while preserving biological variability. Generated via transient Cas9/sgRNA delivery, the polyclonal format yields a mixture of loss-of-function mutations suitable for bulk assays and pathway interrogation.
The host line NCI-H1975 is a lung adenocarcinoma epithelial cell line derived from a non-small cell lung cancer patient. It harbors activating EGFR L858R and T790M mutations, conferring oncogenic signaling and resistance to first-generation EGFR inhibitors. As a clinically relevant model for EGFR-mutant NSCLC, NCI-H1975 is employed to study tumor biology, drug sensitivity, and resistance mechanisms. Introducing JRKL knockout enables dissection of “co-repressor” functions within this defined oncogenic background.
JRKL functions as a nuclear “co-repressor” that physically interacts with KRAB zinc finger proteins (KRAB-ZFPs) and KAP1/TRIM28, forming a complex that also recruits SETDB1, HP1 proteins, and histone deacetylases to establish repressive chromatin. Through this network, JRKL contributes to transcriptional silencing of KRAB-ZFP targets. Additionally, JRKL participates in the DNA damage response and apoptosis regulation, influenced by ATM/ATR signaling and linked to modulation of BCL2 family gene expression.
In NCI-H1975 cells, JRKL disruption may compromise KRAB-ZFP/KAP1-mediated silencing, potentially derepressing genes involved in apoptosis, cell cycle control, or DNA repair. Given the dependence of EGFR-mutant NSCLC on specific transcriptional programs, JRKL knockout allows investigation of how epigenetic silencing networks intersect with oncogenic signaling. Altered DNA damage?Cinduced apoptosis may also affect sensitivity to genotoxic agents and EGFR inhibitors, providing a tool to probe tumor vulnerabilities.
This polyclonal knockout model supports diverse assays: co-immunoprecipitation for JRKL-KAP1 complex integrity, ChIP-qPCR for target promoter occupancy, RT-qPCR of apoptosis-related transcripts (e.g., BCL2 family), and ??H2AX foci quantification for DNA double-strand breaks. Drug sensitivity profiling with EGFR inhibitors such as osimertinib, combined with proliferation and apoptosis assays, is also feasible. For additional details, please contact Ascent Research.
